These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10980325)
1. Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Govitrapong P; Chagkutip J; Turakitwanakan W; Srikiatkhachorn A Psychiatry Res; 2000 Sep; 96(1):41-50. PubMed ID: 10980325 [TBL] [Abstract][Full Text] [Related]
2. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Govitrapong P; Mukda S; Turakitwanakan W; Dumrongphol H; Chindaduangratn C; Sanvarinda Y Neurochem Int; 2002 Oct; 41(4):209-16. PubMed ID: 12106771 [TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. Markianos M; Hatzimanolis J; Lykouras L Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043 [TBL] [Abstract][Full Text] [Related]
5. Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists. Glennon RA; Metwally K; Dukat M; Ismaiel AM; De los Angeles J; Herndon J; Teitler M; Khorana N Curr Top Med Chem; 2002 Jun; 2(6):539-58. PubMed ID: 12052193 [TBL] [Abstract][Full Text] [Related]
6. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. Reynolds GP; Rossor MN; Iversen LL J Neural Transm Suppl; 1983; 18():273-7. PubMed ID: 6135746 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444. Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356 [TBL] [Abstract][Full Text] [Related]
9. Altered platelet serotonin 5-HT2A receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients. Arranz B; Rosel P; Sarró S; Ramirez N; Dueñas R; Cano R; María Sanchez J; San L Psychiatry Res; 2003 May; 118(2):165-74. PubMed ID: 12798981 [TBL] [Abstract][Full Text] [Related]
10. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Reimold M; Solbach C; Noda S; Schaefer JE; Bartels M; Beneke M; Machulla HJ; Bares R; Glaser T; Wormstall H Psychopharmacology (Berl); 2007 Feb; 190(2):241-9. PubMed ID: 17111172 [TBL] [Abstract][Full Text] [Related]
11. Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. Eastwood SL; Burnet PW; Gittins R; Baker K; Harrison PJ Synapse; 2001 Nov; 42(2):104-14. PubMed ID: 11574947 [TBL] [Abstract][Full Text] [Related]
12. Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment. Pandey SC; Sharma RP; Janicak PG; Marks RC; Davis JM; Pandey GN Psychiatry Res; 1993 Jul; 48(1):57-68. PubMed ID: 8105499 [TBL] [Abstract][Full Text] [Related]
13. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Pralong D; Tomaskovic-Crook E; Opeskin K; Copolov D; Dean B Schizophr Res; 2000 Jul; 44(1):35-45. PubMed ID: 10867310 [TBL] [Abstract][Full Text] [Related]
14. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain. Sumiyoshi T; Ichikawa J; Meltzer HY Neuropsychopharmacology; 1997 Mar; 16(3):183-90. PubMed ID: 9138434 [TBL] [Abstract][Full Text] [Related]
15. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Verhoeff NP; Meyer JH; Kecojevic A; Hussey D; Lewis R; Tauscher J; Zipursky RB; Kapur S Psychiatry Res; 2000 Oct; 99(3):123-35. PubMed ID: 11068194 [TBL] [Abstract][Full Text] [Related]
16. The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats. Skrebuhhova-Malmros T; Pruus K; Rudissaar R; Allikmets L; Matto V Pharmacol Biochem Behav; 2000 Oct; 67(2):339-43. PubMed ID: 11124399 [TBL] [Abstract][Full Text] [Related]
17. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125 [TBL] [Abstract][Full Text] [Related]
18. The effect of maternal ketanserin treatment on foetal 5-HT receptor function in umbilical cord artery of pre-eclamptic patients. Hanff LM; Gupta S; MaassenVanDenBrink A; Steegers EA; Saxena PR; Vulto AG; Visser W Neonatology; 2007; 92(4):240-7. PubMed ID: 17556842 [TBL] [Abstract][Full Text] [Related]
19. MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. Mészáros Z; Borcsiczky D; Máté M; Tarcali J; Tekes K; Magyar K J Neural Transm Suppl; 1998; 52():79-85. PubMed ID: 9564610 [TBL] [Abstract][Full Text] [Related]
20. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia. Singh AN; Barlas C; Saeedi H; Mishra RK J Psychiatry Neurosci; 2003 Jan; 28(1):39-47. PubMed ID: 12587849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]